Johnson & Johnson (JNJ) Could Be 33% Below Fair Value Following OTTAVA FDA ClearanceSimplywall·1 day ago, 08:17 PMJNJ+1.59%
Johnson & Johnson | 10-Q: FY2026 Q2 Revenue Beats Estimate at USD 25.31 BEarnings Watch·1 day ago, 03:07 PMJNJ+1.59%
J&J Finally Has a Rival to da Vinci. 1 Number in Intuitive Surgical’s Last Quarter Says It Won’t Be Enough to Move the Needle for JNJ Stock.Barchart Option·1 day ago, 02:16 PMISRG+1.65%JNJ+1.59%
J&J names C1DO1, Curium Life Tech, iQ Surgical as Polyphonic AI Fund for Surgery cohort at SRS meetingPUBT·1 day ago, 09:00 AMJNJ+1.59%
J&J Says TECVAYLI+TALVEY Cuts Risk Of Disease Progression Or Death By 89% In Multiple Myeloma Trialrttnews·1 day ago, 08:09 AMJNJ+1.59%
Johnson & Johnson posts press release on MonumenTAL-6 multiple myeloma trial resultsPUBT·1 day ago, 07:30 AMJNJ+1.59%
Johnson & Johnson's Ottava gets FDA approval; Goldman launches private-company investing platformCoinLive·2 days ago, 02:05 PMJNJ+1.59%GS-D+0.31%
NVIDIA Open Sources First GPU-Accelerated Medical Physics Simulation FrameworkNVIDIA Blog·2 days ago, 08:05 AMNVDA-0.92%NVDU-1.78%
Johnson & Johnson Innovation to host virtual pitch session for oral peptide delivery challenge finalistsPUBT·2 days ago, 07:13 AMJNJ+1.59%
Johnson & Johnson wins FDA De Novo clearance for OTTAVA robotic surgery system in USPUBT·Jul 22 at 06:04 AMJNJ+1.59%
